Biohaven falls as genetic disorder drug fails to meet goal in late-stage study

Biohaven

25/11/2024 13:26

** Shares of drug developer Biohaven Ltd  BHVN.N  fall 14.4%
to $39.02 premarket
    ** BHVN says its experimental drug, taldefgrobep alfa, did
not meet the main goal of improving muscle function in patients
with a rare neuromuscular disorder called spinal muscular
atrophy in a late-stage study
    ** Taldefgrobep alfa is designed to block myostatin, a
protein that limits muscle growth, which helps increase muscle
mass and improve muscle function
    ** However, the drug showed positive effects on body
composition, such as reducing fat mass, supporting its potential
as an obesity treatment, co says
    ** As of last close, stock has risen 6.5% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))